Trial · NCT02807857
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Baseline (Visit 1) | Enrolled and Follow-up Set included. Due to missing left ventricular ejection fraction (LVEF) values, some patients could not be classified. | Participants | NUMBER |
| PRIMARY | Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose | Month 6 | Follow-Up set | Percentage of Patients | NUMBER |
| SECONDARY | Duration of Heart Failure | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Participants | NUMBER |
| SECONDARY | Number of Patients With Current Use of Concomitant Compound | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Participants | NUMBER |
| SECONDARY | Number of Follow-Up Patients With Current Use of Concomitant Compound at Visit 2 | 6 months (Visit 2) | Follow-Up Set | Participants | NUMBER |
| SECONDARY | Percentages of Clinically Stable Patients for Whom the Cardiologist and/or Primary Care Physician Optimizes Treatment Post Referral, Stratified According to Key Baseline Characteristics | 6 months | Follow-Up Set | Percentage of Patients | NUMBER |
| SECONDARY | Number of Patients With Different NT-proBNP Level Categories | One measurement in all consecutive patients at baseline (Visit 1) | Enrolled Set and Follow-Up Set | Participants | NUMBER |
| SECONDARY | Percentages of Clinically Stable Patients | Baseline (Visit 1) | Enrolled Set | Percentage of Participants | NUMBER |
| SECONDARY | Number of Patients by Cardiologist Prescription Practice Per Country/Region | 6 months | Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Change of NT-proBNP Levels in Clinically Stable Chronic Heart Failure Patients With and Without Treatment Optimization 10 Months After Baseline | 10 months | Follow-Up Set | pg/mL | MEAN |
| SECONDARY | Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months) | Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3) | Enrolled Set for Visit 1 (Baseline) and Follow-Up Set (Visit 2 and 3) for those clinically stable patients who entered the prospective period of the study | Scores on a scale | MEDIAN |
| SECONDARY | Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months) | Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3) | Enrolled Set for Visit 1 (Baseline) and Follow-Up Set (Visit 2 and 3) for those clinically stable patients who entered the prospective period of the study | Utility Index Score | MEDIAN |
| SECONDARY | Number of Patients in Different Living Conditions | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients in Different Employment Status | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients With Smoking Status | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients From Different Geographical Regions | Baseline (visit 1) | Enrolled Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients With Health Insurance Status | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients at Different Educational Level | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients Per Primary Etiology of Heart Failure | Baseline (Visit 1) | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
| SECONDARY | Number of Patients With Heart Failure (HF)-Related Hospitalizations in the Previous 12 Months Prior to Baseline, and During the Study | Baseline (Visit 1), 6 months, 10 months | Enrolled Set and Follow-Up Set | Number of Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02807857/outcomes